Fragment designation raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-01-30. Anything still debated is marked as such rather than presented as settled.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | Linear, fifteen residues |
| Sequence | GEPPPGKPADDAGLV | Single-letter amino acid code |
| Approximate mass | 1419 Da | Value reported for the free peptide |
| Reported origin | Fragment of a gastric juice protein | Used as the design template |
| Common synonyms | Body protection compound 157; PL 14736 | Naming varies across papers and suppliers |
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Purity is ordinarily reported as a percentage from reverse-phase high-performance liquid chromatography, where the area of the main peak is compared with the total peak area. Identity is confirmed by mass spectrometry, since the measured mass can be checked against the value calculated from the sequence. Some certificates also include amino acid analysis or sequence confirmation by tandem mass spectrometry. A single purity number does not describe the profile of related impurities, so the underlying chromatogram and spectrum usually carry more information than the headline figure.
Material of this kind is sold for laboratory research, and labels typically state that it is not intended for human or veterinary use. In many countries it is not an approved medicine, and sports antidoping rules place it among prohibited non-approved substances. Buyers commonly review a certificate of analysis, an independent test report, and the declared storage conditions. Batch-to-batch variation in purity and in counterion content is possible, and how much that variation affects experimental outcomes remains an open question.
Lyophilized peptide is normally kept at minus twenty degrees Celsius or colder, away from light and moisture. Powder held under those conditions is widely treated as stable for long periods, although published stability studies for this exact sequence are sparse and often come from suppliers rather than independent laboratories. Once dissolved, solutions are generally handled cold and used within a short window, because peptide bonds can hydrolyze over time. Repeated freeze-thaw cycles are usually avoided to limit losses, and exact shelf-life figures depend on the buffer and the concentration involved.
Lyophilized peptide powder is generally stored at minus twenty degrees Celsius or lower and kept away from light and moisture. Under these conditions degradation is slow, and sealed vials remain stable for extended periods. Once dissolved, the material is less stable, particularly in aqueous buffers near neutral pH, where hydrolysis and oxidation proceed faster. Solutions are usually kept cold and used within days to weeks. Repeated freeze-thaw cycles are avoided because they encourage aggregation.
Identity and purity are established using reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities and yields a percentage purity. Mass spectrometry, typically with electrospray ionization, confirms the molecular mass against the expected value. Amino acid analysis or peptide mapping provides additional sequence confirmation. These methods are complementary, since chromatography measures how much material is present while mass spectrometry verifies what that material is. A certificate of analysis normally reports both.
The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.
Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.
BPC-157 is a synthetic peptide built from fifteen amino acid residues. Its sequence comes from a larger protein fragment that researchers isolated from human gastric juice and described as a body protection compound. The fragment contains glycine, glutamic acid, five prolines, lysine, alanine, two aspartic acids, leucine, and valine. The number 157 in the name refers to the position of the stretch within the parent protein. Material used in laboratories is manufactured rather than extracted from stomach fluid.
== Further reading == May RM, Anderson RM (1991). Infectious diseases of humans: dynamics and control. Oxford: Oxford University Press. ISBN 0-19-854040-X. Vynnycky E, White RG, eds. (2010). An Introduction to Infectious Disease Modelling. Oxford: Oxford University Press. ISBN 978-0-19-856576-5. Capasso V (2008). Mathematical Structures of Epidemic Systems. 2nd Printing. Heidelberg: Springer. ISBN 978-3-540-56526-0. Carlson CS, Rubin DM, Heikkilä V, Postema M (2021). "Extracting transmission and recovery parameters for an adaptive global system dynamics model of the COVID-19 pandemic". 2021 IEEE Africon (PDF). pp. 456–459. doi:10.1109/AFRICON51333.2021.9570946. ISBN 978-1-6654-1984-0. S2CID 239899862.
== Career and research == To juggle parenting and research, Masur moved to the new Medical School at Mount Sinai as an Instructor (part-time) in the Department of Physiology and Biophysics in 1968. where the chairman also provided her with a full-time research assistant. Masur continued as a research associate at Columbia University completing her post-doctoral training in cytochemistry. In collaboration with Eric Holtzman she hypothesized that organelle membrane insertion and removal from the cell surface was the basis for hormone induced alteration in cell membrane permeability. Interest in cell-matrix interaction led her to the cornea where she studied the roles of the extracellular matrix, cell-cell interactions and soluble factors in the wound healing process using a corneal stroma model. Masur's laboratory was funded for 35 years by the National Institutes of Health to explore the hormonal control of membrane transport as well as the cellular mechanisms of wound healing. Her lab determined that myofibroblasts and fibroblasts in the cornea are not "terminally differentiated".
==== Challenges ==== Cell culture using droplet-based microfluidics has created many opportunities for research that is inaccessible in conventional platforms, but also has many challenges. Some of the challenges of cell culture in droplet-based microfluidics are common to other microfluidic culture system. First, nutrient consumption should be re-evaluated for a specific microfluid system. For example, glucose consumption is sometimes increased in microfluidic systems (depending on the cell type). The medium turnover is sometimes faster than in macroscopic culture due to reduced culture volumes, thus the volumes of the medium used must be adjusted in each cell line and device. Secondly, the cellular proliferation and behavior may differ depending on the microfluidic systems, a determining factor is the culture surface area to media volume, which vary from one device to another. One report found that proliferation was impaired in the microchannels; increased glucose or serum supplementation did not address the problem for his specific case. Thirdly, the pH regulation must be controlled. PDMS is more permeable to CO2 than to O2 or N2, thus, the dissolved gas level during incubation should be adjusted to reach the expected pH condition.
=== Canada === Health Canada classifies VOCs as organic compounds that have boiling points roughly in the range of 50 to 250 °C (122 to 482 °F). The emphasis is placed on commonly encountered VOCs that would have an effect on air quality.
Atomic structure deals with the atoms of the materials, and how they are arranged to give rise to molecules, crystals, etc. Much of the electrical, magnetic and chemical properties of materials arise from this level of structure. The length scales involved are in angstroms (Å). The chemical bonding and atomic arrangement (crystallography) are fundamental to studying the properties and behavior of any material.
Sources: en.wikipedia.org
It is unknown whether intensive or conventional blood glucose control is better for diabetic foot ulcer healing. A 2020 Cochrane systematic review evaluated the effects of nutritional supplements or special diets on healing foot ulcers in people with diabetes. The review authors concluded that it's uncertain whether nutritional interventions have an effect on foot ulcer healing and that more research is needed to answer this question. Skin grafting and tissue replacements can help improve the healing of diabetic foot ulcers. A 2021 systematic review concluded that there was no strong evidence about the effects of psychological therapies on diabetic foot ulcer healing and recurrence.
== Export == Sinokrot holding has expanded their businesses of medjoul dates (Pal Gardens Agriculture Company) to the european markets. Building relationships with big European Dates distributors such as Dadelskopen.
=== Research === A major source of bubble instability is when a wide variety of sizes of bubbles are created, gases in smaller bubbles diffuses or disperses into larger bubbles. This is due to their differing Laplace pressures. As of 2023, technologies to control bubble size, distribution and movement were difficult to employ during production. "Advanced" research was underway, including by companies such as Nestlé. In 2013, scientists released the results of experimental research on the impact of phospholipids on aerating cocoa butter. The research found that although all phospholipids tested made cocoa butter foam more, the foam's stability varied by type of phospholipid. The final cocoa butter was also observed to be more stable when the process was undertaken at lower temperatures.
In his first reelection bid, Mizell defeated Democrat James G. White, 68,937 (58.1 percent) to 49,663 (41.9 percent). He was endorsed that year by Americans for Constitutional Action (ACA). Charles McManus, the ACA's president, said, "He has repeatedly stood for fiscal responsibility; firm responsible opposition to the Communists; and for law and order in our streets and institutions of learning." In a 1971 speech to Congress, Mizell voiced his support for MLB's antitrust exemption. "[T]hrough baseball, opportunities have been afforded to young men who otherwise would not have been able to fully enjoy the American dream. Baseball builds character into young men who are going to be the leaders of the future." In 1972, he trounced former Arkansas Congressman Brooks Hays, who had moved to North Carolina, 101,375 (64.8 percent) to 54,986 (35.2 percent). During this term, he was a cosponsor of House Resolution 6992, which proposed equal rights to broadcast media outlets for the chance to broadcast sporting events. In 1972, he chaired a committee that tried to set up a Billy Graham Crusade in Washington, D.C., in 1973. Mizell opposed the Appalachian Power Company's Blue Ridge Power Project, a plan to build two dams on the New River. He was concerned about the project's impact: "Changing the basis for this environmental destruction from ‘pollution‐dilution’ to ‘power crisis’ does not lessen or eliminate the environmental destruction itself...Just as much land will . . . be flooded.
synonymous mutation Also synonymous substitution or samesense mutation. A type of mutation in which the substitution of one nucleotide base for another results, after transcription and translation, in an amino acid sequence which is identical to the original unmutated sequence. This is possible because of the degeneracy of the genetic code, which allows different codons to code for the same amino acid. Though synonymous mutations are often considered silent, this is not always the case; a synonymous mutation may affect the efficiency or accuracy of transcription, splicing, translation, or any other process by which genes are expressed, and thus become effectively non-silent. Contrast nonsynonymous mutation.
Sources: en.wikipedia.org
It is a synthetic fifteen-amino-acid peptide whose sequence matches part of a protein found in human gastric juice. It is made by chemical synthesis, not purified from tissue. The name derives from an early fragment label, not from a molecular weight.
The sequence corresponds to a segment of a naturally occurring gastric protein, so related sequence material exists in the body. The peptide itself as sold and studied is a laboratory-synthesized product. Whether an identical free peptide circulates naturally is not established.
No major regulatory agency has approved it as a medicine for any indication. It appears in research supply channels and, in some jurisdictions, in compounded preparations. Clinical use therefore sits outside standard approved-product pathways, and regulatory status varies by country.
Human data are limited. Most evidence comes from animal experiments and from small or uncontrolled reports. The absence of large trials means clinical effects and safety are not firmly established.